Celgene Shareholders Should Take the Money and Run, Says Wall Street

(Bloomberg) -- Bristol-Myers Squibb’s $74 billion plan to acquire Celgene Corp. came as a surprise to the Street. “Take it!” Leerink analyst Geoffrey Porges advised Celgene investors, while Jefferi...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.